Yet Another Value Podcast cover image

Caligan Partners' Dave Johnson on MorphoSys' $MOR change from royalty play to traditional biotech

Yet Another Value Podcast

00:00

Pelopressa: The Greatest Invention in the History

The average life expectancy of somebody with thrombocytopenia is nine months. Some people have been on this drug for three or four years after the trial. They purposely went after that high risk patient group. And it's really interesting when we dug in the Nevada Clax, Nevada Clax was a drug that was on the shelf at Abby for 20 plus years. It's targeted to dual targeting mechanism and knocks down platelets.

Transcript
Play full episode

The AI-powered Podcast Player

Save insights by tapping your headphones, chat with episodes, discover the best highlights - and more!
App store bannerPlay store banner
Get the app